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Abstract
Background: Antibodies to citrullinated proteins (ACPA) occur years before RA diagnosis. Porphyromonas gingivalis
expresses its own peptidylarginine deiminase (PPAD), and is a proposed aetiological factor for the ACPA response.
Smoking is a risk factor for both ACPA-positive RA and periodontitis. We aimed to study the relation of these
factors to the risk of RA in a prospective cohort.
Methods: We performed a nested case–control study by identifying pre-RA cases in four populations from the
European Prospective Investigation into Cancer and nutrition, matched with three controls. Data on smoking and
other covariates were obtained from baseline questionnaires. Antibodies to CCP2 and citrullinated peptides
from α-enolase, fibrinogen, vimentin and PPAD were measured. Antibodies to arginine gingipain (RgpB) were
used as a marker for P.gingivalis infection and validated in a separate cohort of healthy controls and subjects
with periodontitis.
Results: We studied 103 pre-RA cases. RA development was associated with several ACPA specificities, but
not with antibodies to citrullinated PPAD peptides. Antibody levels to RgpB and PPAD peptides were higher
in smokers but were not associated with risk of RA or with pre-RA autoimmunity. Former but not current
smoking was associated with antibodies to α-enolase (OR 4.06; 95 % CI 1.02, 16.2 versus 0.54; 0.09-3.73) and
fibrinogen peptides (OR 4.24; 95 % CI 1.2-14.96 versus 0.58; 0.13-2.70), and later development of RA (OR 2.48;
95 % CI 1.27-4.84 versus 1.57; 0.85-2.93), independent of smoking intensity.
Conclusions: Smoking remains a risk factor for RA well before the clinical onset of disease. In this cohort,
P.gingivalis is not associated with pre-RA autoimmunity or risk of RA in an early phase before disease-onset.
Antibodies to PPAD peptides are not an early feature of ACPA ontogeny.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
disease of synovial joints with a prevalence of 0.5-
1 %. An autoimmune pathogenesis is supported by
the strong association with anti-citrullinated protein/
peptide antibodies (ACPA), which occur in 50-80 %
of cases and may be detected many years before the
onset of clinical symptoms. There may therefore be a
lengthy pre-clinical stage of RA with different phases,
including systemic autoimmunity without symptoms,
symptoms in the absence of arthritis, and unclassified
arthritis [1]. Importantly, risk factors for one phase
may not be so for others. ACPA responses are char-
acterised by differing but overlapping patterns of re-
activity to several citrullinated autoantigens, and the
number of such specificities increase prior to the clin-
ical onset of joint disease [2–4]. Recent data suggest
that the epitopes that break tolerance may differ be-
tween individuals, and from those most strongly asso-
ciated with the clinical onset of disease, indicating
that epitope spreading may be intimately related to
disease onset [5].
The presence of ACPA in the absence of clinical or
imaging evidence of synovitis suggests an origin out-
side of the joint, and commonly proposed sites in-
clude periodontal tissue [6] and the lungs [7]. Along
with others, our group has investigated the relation-
ship of periodontitis with RA, and infection with
Porphyromonas gingivalis in particular [8–12]. P.gingi-
valis codes for a bacterial peptidyl arginine deiminase
(PPAD) enzyme that differs from human PAD en-
zymes but is capable of citrullinating human proteins
[11, 13]. We have also shown that citrullinated pep-
tides from PPAD are a target of the ACPA response
in a subset of patients with RA [10], though it re-
mains unclear whether this response is driven by
citrullination of PPAD [14] or whether it is part of a
polyreactive ACPA response.
Smoking is a known risk factor for the development
of ACPA-positive RA in Northern European and
American populations [15–17], but few previous stud-
ies have addressed the relationship of smoking with
specific subsets of ACPA in the years before disease
onset [18], or whether smoking is a risk factor for
RA in other populations. Smoking is also a risk factor
for periodontitis, [19, 20] and so an untested hypoth-
esis could be that smoking increases the risk of RA
through promoting periodontal disease.
In this study we present a cohort of southern European
subjects who donated blood prior to the onset of RA, and
investigate the associations of smoking, antibodies to P.
gingivalis arginine gingipain (RgpB), and citrullinated
PPAD peptides, with the risk of RA and pre-RA
autoimmunity.
Methods
Cohorts
EPIC is a multicentre, pan-European prospective cohort
study designed to investigate the association between
diet and cancer, as well as other diseases, in apparently
healthy populations [21]. We undertook a nested
case–control study to investigate risk factors for RA,
by identifying incident RA cases and matched con-
trols amongst subjects enrolled in four EPIC cohorts:
Naples (5062 females, recruited 1993–97), Turin
(6047 males and 4557 females; recruited 1993–98)
and Ragusa (3053 males and 3350 females; recruited
1993–97) in Italy, and Murcia (2685 males and 5831
females, recruited 1992–96) in Spain.
Baseline questionnaires collected detailed data on diet,
physical activity and lifestyle factors (current and lifetime
history). Smoking data included the age at starting and
stopping, and the number of cigarettes smoked currently
and at ages <30, 30–40, 40–50 and >50. This allowed
calculation of a lifetime average number of cigarettes/
day. Alcohol intake at recruitment was estimated by
grams per day. Physical examination collected data on
height, weight and waist circumference. In each centre,
blood for serum was collected at baseline, transferred to
a local laboratory at 5-10 °C whilst protected from
light, and following processing, stored in 0.5 ml
straws at −196 °C in liquid nitrogen. Samples for this
study were retrieved and sent on dry ice to a central
laboratory where they were analysed blinded to case/
control status.
Case ascertainment
In Murcia, RA cases were identified by linkage with pri-
mary health care records (International Classification of
Primary Care code L88) and prescriptions of disease-
modifying anti-rheumatic drugs, and linkage using ICD
codes with hospital discharge (ICD9 – 714) and mortal-
ity databases (ICD10 – M05 and M06). In Naples, RA
cases were identified by linkage with hospital discharge
databases and information from systematic telephone
follow-up of participants. In Turin, RA cases were iden-
tified by linkage with hospital discharge databases and a
drug prescription database with a disease-specific code.
In Ragusa, cases were identified by linkage with hospital
discharge databases. All RA case identification was
undertaken in 2011.
RA cases were then validated by medical record review
to confirm a physician diagnosis of RA and to confirm
date of diagnosis. Additional information was extracted
to assess fulfilment of 1987 (and 2010) ACR classifica-
tion criteria [22, 23].
In Murcia, 80 potential cases were identified and 38
validated as having a physician’s diagnosis of RA, all of
which met 1987 criteria. In Naples, 24 of 48 potential
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cases were validated, all of which met 1987 criteria. In
Turin, 54 of 59 potential cases were validated however,
due to missing data, only 20 were confirmed as meeting
1987 criteria, with an additional case meeting 2010 cri-
teria. In Ragusa 8 of 9 cases were confirmed as having a
physician diagnosis of RA, but again, due to missing
data, only 1 case could be confirmed as meeting 2010
criteria. This yielded a total of 124 cases with a physician
diagnosis of RA (84 of which were also confirmed as
meeting classification criteria), of which 113 were inci-
dent cases (pre-RA), having being diagnosed with RA
after their baseline visit, 10 prevalent, with a diagnosis
preceding their baseline visit, and one had a missing
diagnosis date. Samples were available for 103 pre-RA
cases with a physician diagnosis, used in the analysis
here, of which 62 (60 %) were also confirmed as meeting
1987/2010 criteria, the remainder having incomplete
available data to ascertain fulfilment of criteria. However
where full data was available, there was a high concord-
ance between physician diagnosis and meeting classifica-
tion criteria. Mean age at enrolment was 51 (sd 7.5) and
78 % were female. The median time to diagnosis in the
pre-RA cases was 7 years (range 1.7-15.8 years).
Three controls were randomly selected from living co-
hort members and matched for every individual case by
age at blood collection (±1 year), sex, centre, date
(±2 months) and time (±3 h) of baseline blood collec-
tion, and fasting status at blood collection (<3/3-6/>6 h).
Consent was given by all participants and the study
was approved by the International Agency for Research
on Cancer (IARC) review board as well as by the local
committees of participating EPIC centres.
Laboratory methods
IgM rheumatoid factor (RF) was assayed by particle ag-
glutination following the manufacturer’s recommenda-
tions (Serodia-RA, Fujirebio Inc, Tokyo) and with
agglutination at a dilution of 1:40 considered positive.
ELISA method for peptides
Anti-CCP2 antibodies were measured by commercial
ELISA (DIASTAT, Eurodiagnostica, Malmö, Sweden).
Sera were further tested for antibodies to immunodo-
minant peptides from 3 established citrullinated
autoantigens in RA, α-enolase (CEP-1; 5KIHA-cit-EIFDS-
cit-GNPTVE21) [9], vimentin (cVim; 59VYAT-cit-SSAV-
cit-L-cit-SSVP74) and fibrinogen (cFib; β chain 36NEEG
FFSA-cit-GHRPLDKK52) [24], as well as two citrullinated
PPAD peptides (CPP3, AKTDSYWT-cit-DYTGWFAMYD
and CPP5, LAPNKILI-cit-KVPDNHPQH) [10], with cys-
teines at the end of each peptide to facilitate cyclisation.
Arginine-containing control peptides for all assays were
run in parallel. Ninety-six well plates were coated with
peptide at 10 μg/ml overnight at 4 °C, washed with PBS-
Tween (0.05 %) and blocked with 2 % BSA for 2 h. Sam-
ples were diluted 1:100 in RIA buffer (10 mM Tris, 1 %
BSA, 350 mM NaCl, 1 % Triton-X, 0.5 % Na-
deoxycholate, 0.1 % SDS) and added in duplicate for 1.5 h.
Plates were washed as described above and incubated with
peroxidase-conjugated mouse anti-human IgG (Hybrid-
oma Reagent Laboratory, Baltimore, USA) (diluted
1:3000) for 1 h at room temperature. After a final wash,
bound antibodies were detected with tetramethylbenzi-
dine (TMB) substrate (Biolegend, San Diego, USA). The
reaction was stopped by the addition of 1 M H2SO4 and
absorbance measured at 450 nm. A standard curve was
used for the ELISAs except those incorporating uncitrulli-
nated fibrinogen and α-enolase peptides where reactivity
was rare.
ELISA method for RgpB
ELISA plates were coated with 100 μl/well of 5 μg/ml
RgpB or coating buffer alone (50 mM carbonate buffer,
pH 9.5), and incubated overnight at 4 °C. Wells were
washed with PBS-Tween (0.05 %) and blocked with 2 %
BSA in PBS for 2 h at room temperature. Serum diluted
1:200 in RIA buffer, was added in duplicate, and incu-
bated for 1.5 h at room temperature. Plates were washed
as described above and incubated with peroxidase-
conjugated mouse anti-human IgG (1:3000) in RIA-
buffer for 1 h. After a final wash, bound antibodies were
detected with TMB substrate. The reaction was stopped
after 5 min by the addition of 1 M H2SO4 and absorb-
ance measured at 450 nm. A standard curve was in-
cluded on each plate.
Validation of anti-RgpB antibodies as a marker of P.gingivalis
infection
39 patients with previously untreated chronic periodon-
titis were recruited from Glasgow Dental Hospital, along
with 30 healthy control subjects of a similar age and
gender, as previously described [25, 26]. Each periodon-
titis subject had a minimum of 18 teeth with at least two
non-adjacent teeth with periodontal pockets of ≥5 mm,
5 mm or more of attachment loss, and radiographic evi-
dence of bone loss. Blood and dental plaque samples
were taken prior to treatment, and carriage of P.gingiva-
lis was determined by PCR of bacterial plaque DNA
using P.gingivalis-specific 16S primers as previously de-
scribed [25, 26]. Serum samples for these subjects were
tested for anti-RgpB antibody levels.
Statistical analysis
The 98th percentile of the non-RA control population
included in this study was used to calculate cut-offs for
positivity for the ACPA and RgpB ELISAs, with the ex-
ception of the commercial anti-CCP2 assay where the
manufacturer’s cut-off (>5 units) was used. We also
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categorised the anti-RgpB antibody response into four
groups based on antibody levels.
Differences in median antibody levels among cases
and controls were compared using the Mann–Whitney
U Test. Differences in antibody frequencies among cases
and controls were tested with the Chi square test. Odds
ratios with 95 % confidence intervals were calculated
using conditional logistic regression models. Models
were further adjusted for body-mass index (BMI), waist
circumference, smoking, education, physical activity, and
alcohol intake. These covariates were obtained from
baseline questionnaires at enrolment. Models of smoking
and ACPA were only adjusted for age and sex, due to
the smaller sample size of these groups.
Results
Association of ACPA with pre-RA
The frequency of positive antibodies in the pre-RA
cases compared with controls were: anti-CCP2 (23 %
vs 3 %; p < 0.001), anti-cFIB (18 % vs 2 %; p < 0.001),
anti-CEP-1 (15 % vs 2 %; p < 0.001), and anti-cVIM
(6 % vs 2 %; p < 0.006). IgM RF was present in 22 %
of cases and 4 % of controls (p < 0.001). The highest
adjusted OR for development of RA was seen for
anti-cFib antibodies (OR 10.4; 95 % CI 3.4–32.1;
Table 1). Similar, statistically significant ORs were also
observed with anti-CCP2 and anti-CEP-1 antibodies,
and a trend seen with anti-cVim antibodies.
Time from blood sampling to diagnosis was dichoto-
mised at the median and the frequency of positivity for
antibodies in pre-RA samples ≥7 years before diagnosis
versus <7 years is shown in Table 2, indicating that all of
the antibodies increase in frequency closer to diagnosis
and that no specificity amongst those analysed was
particularly prominent in very early pre-diagnosis
autoimmunity. Median antibody levels to CEP-1 were
higher <7 years before diagnosis compared with ≥7 years
(7.2 vs 3.7 AU; p = 0.02), with a trend to higher numbers
of anti-CEP-1 antibody positive subjects in the <7 years
group (21 % vs 7 %; p = 0.06).
P.gingivalis serology
We have previously found anti-RgpB antibody levels to
be elevated in subjects with periodontitis [10]. The util-
ity of anti-RgpB antibodies as a marker of infection with
P.gingivalis, was further tested in a separate cohort of 30
Table 1 Odds ratios for the association of antibodies to citrullinated peptides, their uncitrullinated controls, rheumatoid factor (RF)
and RgpB, with pre-RA (n = 103). Conditional logistic regression was used with matched controls are referent (n = 309). Cut-off for
antibody positivity is the 98th percentile of matched controls with the exception of anti-CCP2 and RF. RF; rheumatoid factor.
CEP1, cFib and cVim; citrullinated peptides from α-enolase, fibrinogen and vimentin respectively. REP1, Fib and Vim are the
arginine-containing control peptides. CPP3 and CPP5 are immunodominant peptides from PPAD, and RPP3 and RPP5 are the
arginine-containing control peptides. RgpB; arginine gingipain
Antibodies Controls n = 309 Pre-RA n = 103 Crude Fully adjusted model
n (%) n (%) OR (95 % CI) p-value OR (95 % CI)a p-value
CCP2 10 (3) 24 (23) 9.94 (4.28–23.07) <0.001 9.46 (3.89–23.00) <0.001
RF 12 (4) 23 (22) 5.73 (2.79–11.76) <0.001 5.84 (2.66–12.86) <0.001
CEP1 6 (2) 15 (15) 7.11 (2.75–18.35) <0.001 7.26 (2.53–20.82) <0.001
REP1 6 (2) 2 (2) 0.77 (0.15–3.93) 0.748 1.17 (0.22–6.30) 0.853
cFIB 5 (2) 8 (18) 12.01 (4.06–35.55) <0.001 10.44 (3.39–32.10) <0.001
FIB 5 (2) 2 (2) 1.00 (0.19–5.19) 1.000 1.05 (0.20–0.57) 0.957
cVIM 3 (2) 5 (6) 2.84 (0.66–12.05) 0.157 4.84 (0.94–24.94) 0.059
VIM 5 (2) 4 (4) 2.00 (0.53–7.50) 0.304 2.47 (0.62–9.76) 0.199
CPP3 6 (2) 2 (2) 1.00 (0.20–4.95) 1.000 1.54 (0.28–8.31) 0.618
RPP3 5 (2) 5 (5) 2.88 (0.83–9.97) 0.095 3.76 (0.89–15.86) 0.071
CPP5 6 (2) 5 (5) 2.41 (0.73–7.91) 0.147 2.47 (0.71–8.54) 0.154
RPP5 5 (2) 2 (2) 1.20 (0.23–6.19) 0.827 1.78 (0.31–10.39) 0.521
RgpB 12 (4) 3 (3) 0.66 (0.17–2.62) 0.555 0.60 (0.15–2.46) 0.479
RGPB categories
1 (<1280) 123 (44) 51 (50) ref - ref -
2 (≥1280) 75 (27) 29 (28) 0.93 (0.54–1.60) 0.787 0.98 (0.55–1.77) 0.957
3 (≥2560) 68 (24) 20 (19) 0.74 (0.39–1.38) 0.341 0.85 (0.44–1.68) 0.647
4 (≥5120) 12 (4) 3 (3) 0.59 (0.14–2.45) 0.472 0.57 (0.13–2.44) 0.449
a Adjusted for BMI, waist circumference, smoking, education, physical activity, and alcohol intake
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healthy and 39 patients with periodontitis. Using the
95th percentile of the healthy, periodontitis-free controls
as a cut-off, 49 % of patients with periodontitis were
antibody positive (Fig. 1a). Patients with periodontitis
were then divided into two groups based upon the iden-
tification of P.gingivalis 16S rRNA in subgingival plaque
by PCR. Median antibody levels were higher in the PCR-
positive patients and, using a higher cut-off based on the
95th percentile of PCR negative patients and controls,
75 % of PCR positive periodontitis patients were also
antibody positive compared to 9 % of PCR negative pa-
tients (Fig. 1b). This data supports the use of anti-RgpB
antibodies as a marker of infection with P.gingivalis.
No association with pre-RA was seen with antibodies
to RgpB or the two citrullinated PPAD peptides (CPP3
and CPP5). Furthermore, median anti-RgpB antibody
levels did not differ between pre-RA subjects that
were positive or negative for anti-CCP2 (1300 vs
1149 AU; p = 0.36), anti-CEP-1 (1374 vs 1118 AU; p =
0.16), anti-cFib (1300 vs 1112 AU; p = 0.22), anti-cVim
(890 vs 1280 AU; p = 0.32) or RF (1139 vs 1280 AU; p =
0.77), and these subgroups did not differ from controls.
There was also no difference in anti-RgpB antibody levels
between subjects known to be RF positive, through testing
of pre-RA samples or when this data was recorded in their
medical record (‘ever’ RF; n = 62), when compared with
controls (1184 vs 1280 AU; p = 0.81).
Smoking
The frequency of ever smoking was higher amongst pre-
RA cases compared with controls (59 % vs. 47 %, p =
0.02). Compared to never smokers, former smokers were
nearly 3 times more likely to develop RA (OR 2.95, 95 %
CI: 1.40, 6.23; p = 0.004), independent of BMI, waist cir-
cumference, level of education, physical activity and al-
cohol intake. No association between current smoking
and risk of RA was observed. However, an association
was seen for current smokers who were in the lowest in-
tensity bracket (1–15 cigarettes/day: OR 2.15; 95 % CI
1.05–4.37; Table 3). It is conceivable that the lack of as-
sociation with higher intensity current smoking may
reflect a ‘depletion of susceptibles’ i.e. an increased likeli-
hood to develop RA at an earlier age and therefore to
not enrol in the EPIC study. We therefore compared
Table 2 Distribution of antibodies in pre-RA cases stratified by time to RA (dichotomized at median of duration between Ab testing
and RA diagnosis, i.e. 7 years). Cut-offs are based on the 98th percentile of controls with the exception of anti-CCP2 antibodies where
the manufacturer’s cut-off was applied, and RF where a titre of 1:40 was considered positive. RF; rheumatoid factor. CEP1, cFib and
cVim; citrullinated peptides from α-enolase, fibrinogen and vimentin respectively. REP1, Fib and Vim are the arginine-containing
control peptides. CPP3 and CPP5 are immunodominant peptides from PPAD, and RPP3 and RPP5 are the arginine-containing control
peptides. RgpB; arginine gingipain
Antibodies Time to diagnosis
Time <7 years n = 51 Time≥ 7 years n = 52 p-value
RF n (%) 15 (29) 9 (18) 0.179
CCP2 n (%) 15 (27) 10 (20) 0.298
CEP1 n (%) 11 (21) 4 (8) 0.056
REP1 n (%) 2 (4) 0 (0) 0.157
cFib n (%) 13 (25) 6 (12) 0.092
Fib n (%) 1 (2) 1 (2) 0.978
cVim n (%) 4 (10) 1 (3) 0.204
Vim n (%) 3 (6) 1 (2) 0.278
CPP3 n (%) 1 (2) 1 (2) 0.989
RPP3 n (%) 3 (6) 2 (4) 0.663
CPP5 n (%) 2 (4) 3 (6) 0.631
RPP5 n (%) 0 (0) 2 (4) 0.149
RgpB n (%) 2 (4) 1 (2) 0.569
RgpB quartiles
1 (<1280) 25 (48) 26 (51) 0.571
2 (≥1280) 17 (33) 12 (24)
3 (≥2560) 8 (15) 12 (24)
4 (≥5120) 2 (4) 1 (2)
RgpB (u/ml), median (IQR) 1280 (713–1946) 1174 (468–2560) 0.449
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both duration and average number of cigarettes smoked.
As expected, current smokers smoked for longer than
former smokers, but the two groups did not differ in the
average number of cigarettes smoked per day during the
years of smoking (Table 4). Furthermore, neither the in-
tensity (p = 0.64) nor the duration (p = 0.57) of smoking
were associated with the risk of RA.
Smoking and ACPA
Table 4 also shows the relationship between smoking
and ACPA positivity amongst the pre-RA cases. Interest-
ingly, a positive association was only observed between
former smoking and ACPA. This was confirmed by lo-
gistic regression models adjusted for age and sex with
statistical significance for anti-CEP-1 and anti-cFib anti-
bodies (data available upon request). Former pre-RA
smokers were four times more likely to have anti-CEP-1
(OR 4.06, 95 % CI 1.02, 16.2) and anti-cFib (4.24; 95 %
CI 1.2-14.96) antibodies than never pre-RA smokers. In
comparison, no association was seen with current smok-
ing [OR 0.54 (CI 0.09-3.73) for anti-CEP-1 and 0.58
(0.13-2.70) for anti-cFib). Interestingly, median antibody
levels to both CPP5 and its control peptide, were higher
in pre-RA cases who were ever smokers compared to
never smokers (CPP5: 47 vs 31 u/ml; p = 0.04. RPP5: 42
vs 29 u/ml; p = 0.01). In the control group, anti-RgpB
levels were highest in current smokers, intermediate in
former smokers and lowest in never smokers. In the
pre-RA group, antibody levels were highest in the
former smoker group (Fig. 2).
Discussion
In this study of subjects destined to develop RA, we
confirmed that smoking is associated with an increased
risk of RA. However, whilst smoking was also associated
with higher antibody levels to RgpB, a marker of P.gingi-
valis exposure, and to citrullinated peptides from PPAD,
these antibodies themselves were not associated with
later development of RA or with ACPA.
An association between smoking and RA is well-
established, and where observed is usually predominant
in the ACPA positive subset [15–17]. This has been less
well-studied in the pre-RA phase. Although a large
Swedish twin study has recently reported an association
of smoking with ACPA positivity in the absence of a
diagnosis of RA [27], a number of smaller studies of
first-degree relatives (FDRs) have not clearly demon-
strated this [28–31]. Recently however, a Swedish study
found that ‘ever’ smoking was associated with some but
not all ACPA specificities in samples from subjects who
later developed RA [18].
An unexpected finding of this study was that former
but not current smoking was associated with ACPA and
with later development of RA. Whilst this observation
may simply be due to the small study size, it is interest-
ing that former and not current smoking was also asso-
ciated with ACPA. We questioned whether this may
reflect earlier development of RA in heavy smokers, who
as a result did not enrol in the EPIC study. However,
smoking intensity did not differ between former and
current smokers, and was not associated with RA. It is
also possible that development of ACPA may be
Fig. 1 Antibodies to RgpB in (a) healthy controls versus patients
with periodontitis. Using the 95th percentile of the healthy controls as
a cut-off (dashed line), 48 % of patients were positive (p < 0.0001); (b)
healthy and periodontitis subjects that are PCR negative for P.gingivalis
in dental plaque compared to PCR positive periodontitis patients. In
the latter group, 75 % were antibody positive (p < 0.0001). Solid lines
represent medians
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associated with intermittent symptoms such as fatigue
or arthralgia, or with respiratory disease, which may en-
courage individuals to cease smoking. However, it is
noteworthy that smoking also has anti-inflammatory ef-
fects in addition to the more well-known pro-
inflammatory ones [32]. These include inhibition of Th1
and Th17 cytokines via stimulation of α7 nicotinic
acetylcholine receptors [33], and a reduction in im-
munoglobulin levels and antibody responses [34–37].
Furthermore, in animal models, nicotine has been dem-
onstrated to reduce the severity of collagen-induced
arthritis [38], and smoking to delay its onset and reduce
antibody levels to collagen type II and CCP [39]. There-
fore another possibility is that smoking creates a suitable
mucosal environment for generation of ACPA, but with
inhibition of antibody responses until smoking cessation.
Former smoking was associated with a statistically sig-
nificant risk for antibodies to the CEP-1 and cFib
peptides. Other data supports a particularly strong asso-
ciation between anti-CEP-1 and smoking [40–42], and
the relationship of anti-CEP-1 antibody levels and posi-
tivity with time to diagnosis supports recent suggestions
that this antibody specificity may be more closely associ-
ated with clinical onset of RA [5].
A number of studies have suggested an association of
periodontitis with RA [6]. Periodontal infection is poly-
microbial but particular interest has focussed on P.gingi-
valis, in part because it possesses a unique PAD enzyme.
Studies in ACPA positive FDRs and in established RA
have suggested associations of P.gingivalis with RA and
ACPA positivity [29, 43–46]. However, a number of
these studies employed anti-P.gingivalis ELISAs using
whole or sonicated bacteria as evidence of past or
present infection, and the specificity of such assays is
open to question, particularly as the presence of PPAD
may generate citrullinated proteins cross-reactive with
ACPA. Hitchon et al. did report an association between
antibody levels to lipopolysaccharide (LPS) derived from
P.gingivalis, and ACPA, in patients with RA and their
relatives from a North American native population, al-
though the specificity of an assay based on LPS is un-
clear [29]. We did not find increased antibody levels to
RgpB in cases compared with controls. This is similar to
our previous findings in established RA, where the me-
dian anti-RgpB antibody level did not differ from healthy
controls, and was lower than that observed in periodon-
titis [10]. Mikuls TR et al., whilst finding an association
between periodontitis and RA, also did not find an asso-
ciation between antibodies to P.gingivalis specific anti-
gens (outer membrane protein and lipopolysaccharide)
and RA. Neither did they observe an association with
the presence of subgingival P.gingivalis [46]. Similarly,
whilst there was a high frequency of periodontitis found
in patients with new-onset untreated RA, Scher and col-
leagues found the presence of P.gingivalis, as determined
by pyrosequencing of subgingival biofilm, to be associ-
ated with severity of periodontitis but not with RA. Fur-
thermore, antibodies to P.gingivalis specific HtpG P18γ
peptides did not differ between cases and controls [47].
Cumulatively these findings suggest that P.gingivalis may
not account for the association between periodontitis
and RA. It is possible that P.gingivalis may still have a
role in the initiation of RA autoimmunity in a subset of
patients and we have previously proposed that immunity
to autocitullinated PPAD may be such a trigger [10].
However here, we were not able to demonstrate an anti-
body response to two different citrullinated PPAD pep-
tides in patients destined to develop RA, suggesting that
this is not an early feature in ACPA ontogeny. This is
reminiscent of observations made with antibodies to
Table 3 Association of former and current smoking with RA: conditional logistic regression models
Controls Pre-RA Univariate Multivariate
OR (95 % CI) p-value OR (95 % CI)a p-value
Intensity, n (%)
Model 1
Never 133 (44) 36 (36) reference - reference -
Former 59 (19) 28 (28) 1.90 (1.01–3.59) 0.047 2.48 (1.27–4.84) 0.008
Current 80 (26) 30 (30) 1.45 (0.81–2.56) 0.205 1.57 (0.85–2.93) 0.151
Model 2
Never 133 (43) 36 (35) reference - reference -
Current, 1–15 cig/day 39 (13) 20 (20) 1.88 (0.98–3.61) 0.059 2.16 (1.06–4.39) 0.034
Current, >16 cig/day 41 (10) 10 (10) 0.95 (0.42–2.13) 0.905 0.97 (0.43–2.28) 0.974
Former, quit ≤10 years 27 (9) 16 (16) 2.18 (1.04–4.55) 0.039 2.79 (1.29–6.07) 0.009
Former, quit >11 years 32 (11) 12 (12) 1.50 (0.66–3.41) 0.328 2.02 (0.84–4.89) 0.115
Current pipe/cigar/occasional 31 (10) 7 (7) 0.93 (0.36–2.41) 0.888 1.24 (0.46–3.34) 0.670
a Models adjusted for BMI, waist circumference, level of education, physical activity index, and alcohol intake
Fisher et al. BMC Musculoskeletal Disorders  (2015) 16:331 Page 7 of 11
Table 4 Antibodies in pre-RA cases stratified by smoking (never/former/current). Cut-offs are based on the 98th percentile of controls
with the exception of anti-CCP2 antibodies where the manufacturer’s cut-off was applied, and RF where a titre of 1:40 was considered
positive. Ever RF refers to subjects who are known to be RF positive through testing of pre-RA serum or through their post-diagnosis
medical records. RF; rheumatoid factor. CEP1, cFib and cVim; citrullinated peptides from α-enolase, fibrinogen and vimentin respectively.
REP1, Fib and Vim are the arginine-containing control peptides. CPP3 and CPP5 are immunodominant peptides from PPAD, and RPP3
and RPP5 are the arginine-containing control peptides. RgpB; arginine gingipain
pre-RA
Antibodies Never smokers Former smokers Current smokers
n = 36 n = 28 n = 37
RF n (%) 7 (19) 9 (32) 7 (19)
‘Ever’RF n (%) 20 (56) 15 (54) 26 (70)
CCP2 (u/ml), median (IQR) 1.17 (0–59) 1.74 (0–300) 1.26 (0–300)
n (%) 7 (19) 11 (39)* 7 (19)
CEP1 (u/ml), median IQR 4.51 (2.22–69) 15.5 (4.20–355) 3.70 (2.99–152)
n (%) 4 (11) 9 (32)* 2 (5)
REP1 (OD), median (IQR) 0.13 (0.07–0.55) 0.094 (0.05–0.36) 0.076 (0.052–0.27)
n (%) 2 (6) 0 (0) 0 (0)
cFib (u/ml), median IQR 2.53 (1.11–77.24) 3.93 (1.30-320) 1.61 (0.94–217)
n (%) 5 (14) 11 (39) 3 (8)
Fib (OD), median IQR 0.08 (0.06-0.27) 0.09 (0.06–0.26) 0.08 (0.05–0.25)
n (%) 1 (3) 0 (0) 1 (3)
cVim (u/ml), median IQR 14.26 (8.71–114) 29.2 (5.71–401) 16.3 (8.7–240)
n (%) 1 (4) 2 (8) 2 (8)
Vim (u/ml), median IQR 8.25 (4.70–26) 8.20 (5.83–24.3) 7.4 (4.6–44.5)
n (%) 1 (3) 0 (0) 3 (9)
CPP3 (OD), median IQR 0.08 (0.05–0.76) 0.14 (0.08–0.79) 0.10 (0.06–0.33)
n (%) 1 (3) 1 (4) 0 (0)
RPP3 (OD), median IQR 0.09 (0.06–0.80) 0.13 (0.09–0.94) 0.13 (0.06–0.36)
n (%) 3 (8) 2 (7) 0 (0)
CPP5 (u/ml), median IQR 26.8 (14.62–71.48) 52.15 (25.66–122) 39.3 (28.3–60.19)
n (%) 1 (3) 1 (4) 3 (8)
RPP5 (OD), median IQR 27.6 (16.17–35.15) 42.52 (26.8–69.6) 40 (20.99–51.96)
n (%) 0 (0) 0 (0) 2 (5)
RgpB (u/ml), median (IQR) 1191 (599–1444) 1555 (966–2560) 948 (553–1976)
n (%) 1 (3) 2 (7) 0 (0)
categories, n (%)
1 (<1280) 18 (50) 10 (36) 21 (57)
2 (≥1280) 11 (31) 10 (36) 8 (22)
3 (≥2560) 6 (17) 6 (21) 8 (22)
4 (≥5120) 1 (3) 2 (7) 0 (0)
Duration of smoking (years), median (IQR) - 21 (14–29) 26 (21–34)**
Number of cigarettes/day, median (IQR) - 9 (6–18) 13 (8–17)
Time since quitting (years), median (IQR) - 10 (3–16) -
*p<0.05; **P<0.01
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human PAD4 which appear to arise following the ACPA
response [48–50]. Importantly, our data suggest that
while smoking is associated with both P.gingivalis infec-
tion and RA, smoking does not increase the risk of RA
through its association with P.gingivalis.
There are a number of weaknesses in this study.
There were varying methods of case ascertainment
and the use of hospital discharge databases could bias
the cohort towards more severe disease. Due to missing
data, not all patients having a physician’s diagnosis of RA
could be confirmed as meeting classification criteria.
Where such data was available, however, most cases were
found to meet 1987 criteria, giving some confidence for
those cases where full information was not obtainable. We
did not have post-diagnosis samples and we were not able
to determine the final ACPA status for most cases. Simi-
larly we cannot rule out P.gingivalis having a specific role
at the onset of clinical RA, or related to the severity of
RA. Incomplete data also meant that we worked with time
to diagnosis rather than time to symptom onset, meaning
that some cases labelled as pre-RA may in fact have been
prevalent at the time of sampling. However, given that the
median length of symptoms prior to diagnosis is 6–8
months, [51, 52] and the median time to diagnosis in our
study was 7 years, we do not feel that this should invali-
date our findings. Due to the small sample size, we did
not analyse gene-environment interactions. Uniquely, this
is a southern European pre-RA cohort, and the findings
should be replicated in other populations.
Conclusion
In conclusion, we observed that former smoking, rather
than current smoking, was associated with ACPA positiv-
ity and incident RA in a cohort of patients destined to de-
velop RA. This effect was independent of an association
between smoking and P.gingivalis and, if confirmed in
other cohorts, suggests a more complex association of
smoking with ACPA than previously considered.
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